We are live on
!
Find out more
HP
HealthInvest Partners Portfolio holdings
AUM
$372M
1-Year Est. Return
59.89%
This Fund
S&P 500
This Quarter
Est. Return
+5.31%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$213M
AUM Growth
+$48.7M
(+30%)
Cap. Flow
+$48M
Cap. Flow
% of AUM
22.55%
Top 10 Holdings %
Top 10 Hldgs %
61.4%
Holding
41
New
3
Increased
28
Reduced
1
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$5.07M |
| 2 |
Merck
MRK
|
+$4.99M |
| 3 |
Alkermes
ALKS
|
+$4.47M |
| 4 |
Harmony Biosciences
HRMY
|
+$4.11M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$3.66M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IQVIA
IQV
|
+$2.96M |
| 2 |
Molina Healthcare
MOH
|
+$2.82M |
| 3 |
Option Care Health
OPCH
|
+$1.51M |
| 4 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$688K |
| 5 |
MacroGenics
MGNX
|
+$609K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Summit Therapeutics
SMMT
$12.1B
| $1.88M | 0.89% |
+86,013
| New | +$1.2M |
|
27
Immunocore
IMCR
$1.74B
| $1.68M | 0.79% |
54,060
+30,282
| +127% | +$1.1M |
|
28
Krystal Biotech
KRYS
$9.68B
| $1.68M | 0.79% |
9,202
+1,578
| +21% | +$304K |
|
|
AUTL
29
Autolus Therapeutics
AUTL
$620M
| $1.61M | 0.75% |
442,423
+216,278
| +96% | +$863K |
|
30
Corbus Pharmaceuticals
CRBP
$184M
| $1.44M | 0.67% |
69,573
+30,473
| +78% | +$1.56M |
|
31
BridgeBio Pharma
BBIO
$16.4B
| $1.36M | 0.64% |
53,432
| – | – |
|
|
SLNO
32
DELISTED
Soleno Therapeutics
SLNO
| $1.33M | 0.63% |
+26,390
| New | +$1.26M |
|
|
MRSN
33
DELISTED
Mersana Therapeutics
MRSN
| $1.02M | 0.48% |
21,545
+14,149
| +191% | +$624K |
|
|
MREO
34
Mereo BioPharma
MREO
$48.8M
| $822K | 0.39% |
+200,000
| New | +$827K |
|
35
Cabaletta Bio
CABA
$455M
| $795K | 0.37% |
168,522
+104,201
| +162% | +$603K |
|
36
Pharvaris
PHVS
$2.41B
| $636K | 0.3% |
34,328
| – | – |
|
|
37
IQVIA
IQV
$40.1B
| – | – |
-13,984
| Closed | -$2.96M |
|
|
38
MacroGenics
MGNX
$249M
| – | – |
-143,407
| Closed | -$609K |
|
|
39
Molina Healthcare
MOH
$10.2B
| – | – |
-9,500
| Closed | -$2.82M |
|
|
40
Option Care Health
OPCH
$3.61B
| – | – |
-54,395
| Closed | -$1.51M |
|
|
MORF
41
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| – | – |
-20,199
| Closed | -$688K |
|
Similar funds
KP
TCM
SAAM
PC
GIP
PC
DPCM
OCMH
HealthInvest Partners's Q3 2024 Portfolio in Review
As of Q3 2024, HealthInvest Partners held 41 positions worth $213M, up 30% from $164M the previous quarter. Its ten largest holdings account for 61% of the portfolio.
HealthInvest Partners deployed $48M of net new capital in Q3 2024, opening 3 new positions and adding to 28 existing holdings. Its largest new stake was Soleno Therapeutics: 26,390 shares worth $1.33M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Boston Scientific, an estimated $30.3K trimmed.
- HealthInvest Partners's largest Q3 2024 buy was Soleno Therapeutics: 26,390 shares worth $1.33M.
- HealthInvest Partners added most to Neurocrine Biosciences in Q3 2024, an estimated $5.07M increase.
- HealthInvest Partners's biggest Q3 2024 reduction was Boston Scientific, cutting an estimated $30.3K.
- HealthInvest Partners fully exited IQVIA in Q3 2024, selling an estimated $2.96M.
- HealthInvest Partners's ten largest holdings make up 61% of its $213M portfolio in Q3 2024.
- HealthInvest Partners opened 3 new positions and closed 5 in Q3 2024.
- HealthInvest Partners's portfolio value rose 30% quarter-over-quarter to $213M.
Based on HealthInvest Partners's 13F filing for Q3 2024, filed 12 Nov 2024.